Juniper Publishers-Cancer Therapy Oncology International Journal

  Cancer Therapy & Oncology International Journal Abstract The medical devices that are designated to be marketed need to go through a clearance process set forth by FDA. The Premarket notification (PMN) or 510(k) is the most common regulatory pathway in US but poses many challenges to medical device manufacturers. FDA has cleared more than 1, 40,000 medical devices since 1976. This is a clearance process, and not an approval, for medical devices. 510(K) submission has a purpose, a process and should be well understood in order to avoid unnecessary delays and failures. Keywords: Medical device; Regulation; FDA; 510(K); Substantially Equivalent Abbreviations: FDA: Food and Drug Administration, PMA: Premarket Approval; SE: Substantially Equivalent; Introduction Getting a clearance letter from FDA on 510(K) for a medical device is a milestone and the ultimate goal for any medical device manufacturer, be it a small ...

  Cancer Therapy & Oncology International Journal Abstract Neurofibromatosis was first described in 1882 by Friedrich Daniel von Reckling hausen, a German pathologist. Neurofibroma is a benign peripheral nerve sheath tumor that consists of Schwann cells, associated or unassociated with axons, perineural cells, and fibroblasts. Whenever possible, the treatment of choice should be surgical, but the management depends on the location and growth pattern. We present the case of a patient with left axillary neurofibroma without neurofibromatosis (NF) in whom surgery was delayed due to involvement of the brachial plexus, so was sent to radiotherapy, planned and treated with volumetrically modulated arc therapy (VMAT). Keywords: Neurofibroma; VMAT; Radiotherapy; Axillary Tumor; INCART Abbreviations: NF: Neurofibromatosis; VMAT: Volumetrically Modulated Arc Therapy; CRO: Radiation Oncology Center; INCART: Institute Rosa Emilia Sánchez Pérez de Tavares; ...

  Cancer Therapy & Oncology International Journal Abstract Management of patients with glioblastoma multiform requires the concerted efforts of multiple healthcare professionals, including pharmacists. Pharmacists across different practice settings may encounter patients being treated for glioblastoma multiforme. The oral chemotherapy temozolomide is a standard of care forglioblastoma multiforme, with dosing regimens and cycles that require dispensing considerations by the pharmacist as well as careful patient monitoring. Pharmacists should be able to direct the patient with glioblastoma multiforme to payment assistance for this drug as well. Bevacizumab is used to increase progression-free survival in recurrent glioblastoma multiforme, and pharmacists can also aid in the dosing and monitoring of this agent. Sequelae of glioblastoma multiforme include brain edema, seizures, venous thromboembolism, depression, and fatigue. Management of sequelae may includ...

  Cancer Therapy & Oncology International Journal    Abstract Prostate cancer within a younger cohort of men continues to be an increasing problem. With a younger population, greater expectations are present, from erectile function, to continence to oncological outcomes. Significant prostate cancer is increasingly diagnosed in younger men, less than 55 years [1]. In a non-screened population young patients are choosing radical surgery for intermediate and high risk disease [1]. This patient group have high expectations with regards to oncological and functional outcomes. The next question arises, what can we do to improve outcomes? Keywords: robotic radical prostatectomy, outcomes Abbreviations: ERSPC: European Randomized Study of Screening for Prostate Cancer; AUA: American Urological Association Mini Review Early-onset prostate cancer (<55 years), dif...

  Cancer Therapy & Oncology International Journal Abstract Neurofibromatosis type 1 (NF1), formerly known as von Recklinghausen’s disease is a nervous system tumor disorder of variable expressivity. Malignant solitary fibrous tumors (SFT) are rare spindle cell soft tissue tumors. We report a case of a 35-year-old male who presented clinically with NF1 and a mass that mimicked a nerve sheath tumor radiologically, but pathologically was, in fact, a malignant solitary fibrous tumor. Based on a literature review, the association between NF1 and malignant SFT has never been published. Keywords: Neurofibromatosis type 1; Malignant solitary fibrous tumor Abbrevations: SFT: Solitary Fibrous Tumors; NF1: Neurofibromatosis type 1 Mini Review Neurofibromatosis type 1 (NF1) is a multisystem disease characterized by cutaneous findings, as well as benign and malignant tumors o...